If You Invested in Cambiar Aggressive Value ETF (CAMX)

Camurus AB (NASDAQ Stockholm: CAMX) is described in its public communications as an international, science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for patients with severe and chronic diseases. According to the company, new drug products are conceived using its proprietary FluidCrystal® drug delivery technology together with extensive research and development expertise. Camurus reports that it has operations across Europe, the US, and Australia, with headquarters in Lund, Sweden, and that its shares are listed on Nasdaq Stockholm under the ticker CAMX.

Across multiple press releases, Camurus highlights a research and development pipeline that includes products for the treatment of dependence, pain, cancer, and endocrine diseases. The company states that these products are developed both in-house and in collaboration with international pharmaceutical companies. Its communications repeatedly emphasize long-acting formulations intended for conditions that require sustained treatment, such as opioid dependence, acromegaly, gastroenteropancreatic neuroendocrine tumors (GEP-NET), polycystic liver disease (PLD), obesity, and type 2 diabetes.

Core technology and long-acting formulations

Camurus describes FluidCrystal® technology as a proprietary lipid-based system designed to deliver therapeutic levels of an active substance over extended periods, ranging from days to months, using a single injection administered with a prefilled syringe or autoinjector pen. The company explains that, after injection, the solution transforms into a liquid crystalline gel in the tissue, encapsulating the active ingredient and releasing it gradually as the matrix degrades. Camurus notes that this technology is commercially and regulatory validated through market approvals and product sales in Europe, the US, and Australia.

In its collaboration announcement with Eli Lilly and Company, Camurus states that FluidCrystal technology is being applied to long-acting incretin products for cardiometabolic health, based on Lilly proprietary drug compounds. The agreement covers up to four compounds selected from dual and triple receptor agonists and includes an option to add amylin receptor agonists. Camurus presents this collaboration as a way to apply its technology in areas such as obesity and diabetes while maintaining its own commercial focus on central nervous system (CNS) and rare diseases.

Key products and development programs

Camurus highlights several key products and investigational programs in its public information:

• Buvidal® / Brixadi™: Buvidal is described as a buprenorphine prolonged-release solution for subcutaneous injection in a prefilled syringe, indicated for the treatment of opioid dependence within a framework of medical, social, and psychological treatment. It is intended for adults and adolescents aged 16 years or over and is available in multiple weekly and monthly strengths, allowing treatment to be tailored to individual needs. Administration is restricted to healthcare professionals. Camurus states that Buvidal is approved for treatment of opioid dependence in the EU, UK, Switzerland, Australia, New Zealand, and several countries in the Middle East and North Africa.
• Brixadi™: In the US, the same underlying buprenorphine product is marketed under the tradename Brixadi by Camurus’ licensee Braeburn. Camurus reports that the US Food and Drug Administration (FDA) has approved Brixadi as a weekly and monthly extended-release buprenorphine injection for subcutaneous use for the treatment of moderate to severe opioid use disorder in patients who have initiated or are already on transmucosal buprenorphine. Brixadi is administered by healthcare professionals and is distributed under a restricted program (Brixadi REMS Program). The company notes that Brixadi is formulated using FluidCrystal injection depot technology and does not require refrigeration.
• CAM2029 / Oczyesa® / Oclaiz™: CAM2029 is described as an octreotide subcutaneous depot, a ready-to-use, long-acting subcutaneous formulation of octreotide designed for once-monthly administration with a prefilled autoinjector pen. Camurus reports that CAM2029 is under development for three chronic and severe disease indications: acromegaly, gastroenteropancreatic neuroendocrine tumors (GEP-NET), and polycystic liver disease (PLD). The company states that CAM2029 has demonstrated an approximate five-fold higher bioavailability compared to currently approved long-acting intramuscular octreotide, and that its clinical program includes multiple Phase 1, Phase 2, and Phase 3 studies (the ACROINNOVA program in acromegaly, the SORENTO study in GEP-NET, and the POSITANO study in PLD).
• Oczyesa®: Camurus reports that the European Commission has granted marketing authorization for Oczyesa, an octreotide subcutaneous depot (CAM2029), for the maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogs. Oczyesa is described as the first approved once-monthly, subcutaneous octreotide treatment for acromegaly in the EU, designed for convenient self-administration using a prefilled autoinjector pen with a hidden, thin needle. The company notes that Oczyesa is formulated with FluidCrystal technology and is stored at room temperature.
• Oclaiz™ (CAM2029): In the US, the same octreotide subcutaneous depot is referred to as Oclaiz. Camurus states that the FDA has accepted for review a resubmission of the New Drug Application (NDA) for Oclaiz for the treatment of patients with acromegaly and has assigned a Prescription Drug User Fee Act (PDUFA) target action date. The NDA resubmission followed a Complete Response Letter that related to observations during a cGMP inspection at a third-party manufacturer’s facility. The application is supported by data from seven clinical studies, including two Phase 3 trials in the ACROINNOVA program.
• CAM2056: Camurus describes CAM2056 as a long-acting, subcutaneous semaglutide formulation, a glucagon-like peptide-1 (GLP-1) receptor agonist formulated with FluidCrystal technology. In a Phase 1b study in individuals with overweight or obesity, CAM2056 was compared to weekly semaglutide (Wegovy®). The company reports that CAM2056, given as biweekly initiation doses followed by monthly doses, was well tolerated and produced dose-dependent reductions in body weight, hemoglobin A1c (A1c), and fasting glucose, comparable to or exceeding those seen with weekly semaglutide.

Therapeutic focus areas

Camurus’ communications outline several therapeutic focus areas:

• Opioid dependence and addiction: Through Buvidal and Brixadi, Camurus addresses opioid dependence and opioid use disorder. The company cites clinical data showing that weekly and monthly subcutaneous buprenorphine depot formulations can be effective compared with daily sublingual buprenorphine/naloxone, including in individuals using fentanyl. Reported outcomes include high proportions of fentanyl-negative urine samples, reductions in withdrawal symptoms and cravings, and safety profiles consistent with known buprenorphine effects, aside from injection site reactions.
• Endocrine diseases and rare conditions: Camurus focuses on acromegaly, describing it as a rare, serious, and chronic disease typically caused by a pituitary tumor producing excess growth hormone and elevated insulin growth factor-1 (IGF-1) levels. The company notes that acromegaly leads to abnormal growth of bone and tissue, enlarged extremities and facial features, and symptoms such as fatigue, joint pain, headache, visual field defects, excessive sweating, and paresthesia. It cites clinical results indicating that CAM2029/Oczyesa can normalize IGF-1 levels in a higher proportion of patients than placebo, maintain biochemical control over extended periods, and improve symptoms, quality of life, and treatment satisfaction compared to standard of care.
• Polycystic liver disease (PLD): Camurus describes PLD as a rare genetic disorder characterized by progressive growth of liver cysts, leading to severe symptoms and reduced quality of life. The company notes that there is currently no approved pharmacological treatment for PLD. In the POSITANO Phase 2b study, CAM2029 was reported to reduce liver and cyst volume growth compared to placebo and to improve disease symptoms and patient-reported outcomes, with a safety profile consistent with established somatostatin receptor ligands.
• Gastroenteropancreatic neuroendocrine tumors (GEP-NET): CAM2029 is also being evaluated in GEP-NET in an ongoing Phase 3 study (SORENTO), according to Camurus’ descriptions. The company positions this as part of its broader focus on severe and chronic endocrine and oncologic conditions.
• Cardiometabolic diseases: Through the collaboration with Eli Lilly, Camurus is extending its FluidCrystal technology to long-acting incretin-based therapies for cardiometabolic health, addressing areas such as obesity and diabetes. The agreement includes multiple Lilly proprietary compounds targeting incretin and related receptors.

Clinical development and regulatory activity

Camurus’ press releases describe a series of clinical and regulatory milestones. For CAM2029 in acromegaly, the company outlines the ACROINNOVA clinical program, consisting of a 24-week randomized, double-blind, placebo-controlled Phase 3 trial (ACROINNOVA 1) and a 52-week open-label long-term safety and extension trial (ACROINNOVA 2). Reported outcomes include favorable long-term safety, increased biochemical response rates, and continuous improvements in symptom and quality-of-life scores compared to baseline standard-of-care treatment with first-generation somatostatin receptor ligands.

For PLD, Camurus describes the POSITANO Phase 2b study, which met its primary endpoint by showing statistically significant relative reductions in height-adjusted liver volume and total liver cyst volume for CAM2029 compared to placebo. The company notes that CAM2029 has received Orphan Drug Designation for PLD in both the US and EU and for acromegaly in the EU.

In opioid use disorder, Camurus reports that the FDA approval of Brixadi was based on a randomized, active-controlled Phase 3 trial comparing CAM2038 (the depot buprenorphine formulation underlying Brixadi/Buvidal) with daily sublingual buprenorphine/naloxone. The trial met its primary endpoint of non-inferiority for responder rate and a secondary endpoint of superiority in reducing illicit opioid use, with a safety profile consistent with sublingual buprenorphine apart from mild to moderate injection site reactions.

Business collaborations and licensing

Camurus’ public information highlights business collaborations as part of its model. In North America, product rights to Brixadi are licensed to Braeburn, which markets the product in the US. The company also describes a collaboration and license agreement with Eli Lilly, under which Lilly receives exclusive worldwide rights to research, develop, manufacture, and commercialize long-acting incretin products for cardiometabolic health based on FluidCrystal technology. In return, Camurus is eligible for specified upfront, development, regulatory, and sales-based milestone payments, as well as tiered royalties on global net product sales.

Through these collaborations, Camurus combines its drug delivery technology and clinical programs with partners’ commercial and therapeutic area expertise. At the same time, it states that it maintains its own commercial focus on CNS and rare diseases, including dependence and certain endocrine and hepatic conditions.

Geographic footprint and listing

In its descriptions, Camurus states that it has operations across Europe, the US, and Australia. The company is headquartered in Lund, Sweden, and its shares are listed on Nasdaq Stockholm under the ticker CAMX. Its products and candidates are described as being present in multiple regions through approvals such as Buvidal in Europe, Australia, New Zealand, and parts of the Middle East and North Africa, Brixadi in the US, and Oczyesa in the EU and UK.